Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 18/20 | 0.55 |
| ▸ | ITGAV | P06756 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7442644 | 0.88 | ITGB3 (0.68) | ITGB3ITGA2BITGAV | |
| SCHEMBL7449964 | 0.88 | ITGB3 (0.68) | ITGB3ITGA2BITGAV | |
| SCHEMBL7447180 | 0.88 | ITGB3 (0.68) | ITGB3ITGA2BITGAV | |
| Hydrochloric Acid SCHEMBL7450135 | 0.87 | ITGB3 (0.68) | ITGB3ITGA2BITGAV | |
| Trifluoroacetic Acid SCHEMBL7793879 | 0.85 | ITGB3 (0.64) | ITGB3ITGA2B | |
| SCHEMBL7369874 | 0.78 | KDM1A (0.34) | — | |
| SCHEMBL7793872 | 0.78 | KDM1A (0.34) | — | |
| SCHEMBL7373695 | 0.74 | ITGB3 (0.32) | ITGB3ITGA2B | |
| SCHEMBL9092432 | 0.74 | ITGAV (0.50) | ITGB3ITGA2BITGAV | |
| SCHEMBL9093436 | 0.73 | ITGB3 (0.47) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0832077-B1 | IMPROVED ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARM CO (US) | 2001-11-14 | — | — | EP | disclosed |
| WO-1996038426-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |